Gastric Balloon Market
Medical Device

Gastric Balloon Market To Account US$ 152.1 Mn by 2027

Apollo Endosurgery, Inc. and Allurion Technologies, Inc. – Notable Market Participants in Gastric Balloon Market

The gastric balloon is a niche market in nature with limited number of players, having considerable revenue in the gastric balloon market. Most of the companies operating in the gastric balloon market are offering their products in the European and the Middle East region, whereas, only three products have FDA approvals for the commercialization of their products.

The most notable gastric balloon market participants are Apollo Endosurgery, Inc. and Allurion Technologies, Inc., ENDALIS, Helioscopie Medical Implants, LEXEL SRL, MEDSIL, Obalon Therapeutics, Inc., ReShape Lifesciences, Inc., Silimed, and Spatz FGIA, Inc. occupying a considerable share of the market owing to their offerings to the market.

gastric balloon market leaders are involved in activities such as, obtaining approvals to serve a better customer base. For instance, In December, 2018, Obalon received FDA approval of the Obalon Navigation System, which eliminates the need to use x-ray when placing the Obalon Balloon System. The Obalon Navigation System and Touch Inflation Dispenser are expected to be commercially available during the first quarter of 2019 in the United States. Also, during February, 2018, Apollo received approval from the South Korean Ministry of Food and Drug Safety’s (MFDS) for the ORBERA Intragastric Balloon System. Shin Han Systek Co. Ltd. was declared as the exclusive distributor for ORBERA in South Korea. Owing to these approvals, it has been possible for the companies to serve larger customer base as well as provide better weight loss solutions to the patients.

Along with obtaining approvals, various companies have signed agreements in order to strengthen as well as extend its customer base. Additionally various companies are also undergoing other strategic alliances such as collaboration partnerships to garner their significance and remain competitive in the market. Few on the important key developments from the industry are mentioned below:

Year News Region
2018 ReShape acquired the Lap-Band adjustable gastric band system from Apollo Endosurgery, Inc. and that Apollo Endosurgery has acquired the ReShape Balloons product line from ReShape Lifesciences. North America
2018 Obalon received FDA approval of the Obalon Navigation System, which eliminates the need to use x-ray when placing the Obalon Balloon System. The Obalon Navigation System and Touch Inflation Dispenser are expected to be commercially available during the first quarter of 2019 in the United States. North America
2017 Obalon and Sono Bello entered an agreement. Through the agreement the Obalon Balloon System would be used for non-surgical weight loss in Sono Bello centers across the US. North America
2017 Allurion raised $27 million to support Elipse balloon. The funds have been used to both scale manufacturing and set up clinical trials in the U.S. that could eventually make the product available in America. North America